EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bausch & Lomb's enterprise value is $9,534 Mil.
Bausch & Lomb's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $532 Mil. Therefore, Bausch & Lomb's EV-to-EBITDA for today is 17.92.
The historical rank and industry rank for Bausch & Lomb's EV-to-EBITDA or its related term are showing as below:
BLCO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.36 Med: 16.22 Max: 21.52
Current: 17.92
During the past 6 years, the highest EV-to-EBITDA of Bausch & Lomb was 21.52. The lowest was 10.36. And the median was 16.22.
BLCO's EV-to-EBITDA is ranked worse than 54.73% of 486
companies
in the Medical Devices & Instruments industry
Industry Median: 16.29
vs BLCO: 17.92
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Bausch & Lomb EV-to-EBITDA Historical Data
The historical data trend for Bausch & Lomb's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bausch & Lomb's EV-to-EBITDA
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's EV-to-EBITDA falls into.
Bausch & Lomb EV-to-EBITDA Calculation
Bausch & Lomb's EV-to-EBITDA for today is calculated as:
Bausch & Lomb's current Enterprise Value is $9,534 Mil.
Bausch & Lomb's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $532 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Bausch & Lomb's PE Ratio for today is calculated as:
Bausch & Lomb's share price for today is $15.01.
Bausch & Lomb's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.960.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Bausch & Lomb's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Bausch & Lomb (Bausch & Lomb) Business Description
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BLCO has been successfully added to your 